0001193125-10-233466 Sample Contracts

DATED 20 AUGUST 2004 JAGOTEC AG and SKYEPHARMA AG and NITEC PHARMA AG DEVELOPMENT & LICENCE AGREEMENT
Licence Agreement • October 21st, 2010 • Horizon Pharma, Inc. • Pharmaceutical preparations

NOW, THEREFORE, in consideration of the premises, mutual covenants and agreements contained in this Agreement and intending to be legally bound by it, the Parties hereby agree as follows:

AutoNDA by SimpleDocs
MANUFACTURING & SUPPLY AGREEMENT
Supply Agreement • October 21st, 2010 • Horizon Pharma, Inc. • Pharmaceutical preparations

This MANUFACTURING & SUPPLY AGREEMENT (“Agreement”), effective as of 3 August 2007, is entered into between NITEC PHARMA AG, a Swiss corporation having a place of business at Kägenstrasse 17, CH-4153 Reinach, Switzerland (hereinafter referred to as “NITEC”), and JAGOTEC AG, a Swiss corporation having a place of business at Eptingerstrasse 51, CH-4132 Muttenz, Switzerland (hereinafter referred to as “JAGOTEC”; (NITEC and JAGOTEC hereinafter sometimes referred to as “Party” or “Parties”). JAGOTEC is a 100% owned subsidiary of SkyePharma plc and SkyePharma AG is a 100% owned subsidiary of SkyePharma plc.

FIRST AMENDMENT TO AGREEMENT FOR THE PROVISION OF A LOAN FACILITY OF UP TO EURO 7,500,000
Horizon Pharma, Inc. • October 21st, 2010 • Pharmaceutical preparations • England

This First Amendment To Agreement For The Provision Of A Loan Facility Of Up To Euro 7,500,000 (“Amendment”) is made and entered into as of April 1, 2010, by and between Nitec Pharma AG, a company incorporated in Switzerland with number CH-280.3.007.771-0/ (“Borrower”), and Kreos Capital III (UK) Limited, a company incorporated in England and Wales whose company number is 05981165 (“Lender”).

DATED 24th March 2009 NITEC PHARMA AG AND MUNDIPHARMA INTERNATIONAL CORPORATION LIMITED EXCLUSIVE DISTRIBUTION AGREEMENT
Exclusive Distribution Agreement • October 21st, 2010 • Horizon Pharma, Inc. • Pharmaceutical preparations
Master Services Agreement
Master Services Agreement • October 21st, 2010 • Horizon Pharma, Inc. • Pharmaceutical preparations • New York

This Master Services Agreement (this “Agreement”) is entered into the 11th day of September, 2008 between Pharmaceutics International, Inc. (“PII”) with an address at 10819 Gilroy Road, Hunt Valley, Maryland, 21031, Attn: Steve King, Senior Vice President, and Horizon Therapeutics, Inc., with an address at 8025 Lamon Avenue, Suite 110, Skokie, IL 60077 (“Customer”).

TECHNICAL TRANSFER AGREEMENT
Technical Transfer Agreement • October 21st, 2010 • Horizon Pharma, Inc. • Pharmaceutical preparations • New York

This Technical Transfer Agreement (together with the Schedules hereto, this “Agreement”) is entered into as of November 9, 2009 (the “Effective Date”)

Technology Transfer Agreement between Merck KGaA (“Merck”), Frankfurter Strasse 250, 64271 Darmstadt and Nitec Pharma AG (“Nitec Pharma”) Switzerland Preamble
Technology Transfer Agreement • October 21st, 2010 • Horizon Pharma, Inc. • Pharmaceutical preparations

Merck has been marketing corticoids (Fortecortin, Decortin, Decortin H, Solu Decortin H) successfully – primarily in Germany – for many years. In order to support the corticoid business Merck started developing Prednison Night Time Release in 1998, which is a novel galenic formulation using the active agent prednison. For the treatment of rheumatoid arthritis (“RA”) the Project (as defined hereinafter) has not yet entered phase 3 of clinical testing.

PACKAGING and SUPPLY AGREEMENT for the packaging of pharmaceuticals between
Packaging and Supply Agreement • October 21st, 2010 • Horizon Pharma, Inc. • Pharmaceutical preparations

CATALENT GERMANY SCHORNDORF GmbH Steinbeisstraße 2, D-73614 Schorndorf, Germany, hereinafter referred to as “CATALENT” and made effective 29 Sept. 2008, (the “Effective Date”).

Time is Money Join Law Insider Premium to draft better contracts faster.